References
- International Network of Agencies for Health Technology Assessment. What is Health Technology Assessment (HTA)?: International Network of Agencies for Health Technology Assessment; 2019 Available from 2019 Jan 3: http://www.inahta.org/
- Goodman CS. HTA 101. Introduction to health technology assessment: bethesda, US national library of medicines; 2014 Available from 2019 Jan 3: https://www.nlm.nih.gov/nichsr/hta101/HTA_101_FINAL_7-23-14.pdf
- Grande SW, Elwyn G. Chapter 8. The final stretch? How shared decision making extends health technology assessment to meet patient preference. In: Del Llano-Señarís JE, Campillo-Artero C, editors. Health technology assessment and health policy today: a multifaceted view of their unstable crossroads. 1st ed. Springer International Publishing Switzerland: Adis; 2015. p. 131–146.
- Siegfried N, Wilkinson T, Hofman K. Where from and where to for health technology assessment in South Africa? A legal and policy landscape analysis. South Afr Health Rev. Durban: Health Systems Trust. 2017;42–48.
- Department of Health. NHI implementation: institutions, bodies and commissions that must be established. Act no.12 of 2012. Pretoria: Government Gazette; 2017. p. 4–24.
- Department of Health. National health insurance bill, 2018: for broader public comment. Pretoria: Goverment Gazette; 2018. p. 1–84.
- Doherty JE, Wilkinson T, Edoka I, et al. Strengthening expertise for health technology assessment and priority-setting in Africa. Glob Health Action. 2017;10(1):1370194.
- Department of Health. Medicines and related substances act(10 of 1965) regulations relating to a transparant pricing system for medicines and scheduled substances: publication of the guidelines for pharmacoeconomic submissions. Pretoria: Government Gazette; 2013. p. 3–69.
- Stander MP, Bergh M, Miller-Janson HE. A first step towards transparency in pricing of medicines and scheduled substances - publication of guidelines for pharmaco-economic submissions. S Afr Med J. 2013 Oct 11;104(1):10–11. . PubMed PMID: 24388074.
- Carapinha JL. A comparative review of the pharmacoeconomic guidelines in South Africa. J Med Econ. 2017 Jan;20(1):37–44.
- National Institute for Health and Care Excellence. Who we are: national institute for health and care excellence; 2018 Available from 2019 Jan 3: https://www.nice.org.uk/about/who-we-are
- National Institute for Health and Care Excellence. What we do: national institute for Health and care excellence; 2018 Available from 2019 Jan 3: https://www.nice.org.uk/about/what-we-do
- National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013 (PMG9): national institute for health and care excellence; 2013 Available from 2018 Mar 25: https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781
- National Institute for Health and Care Excellence. Social value judgements: principles for the development of NICE guidance. Second ed. London: National Institute for Health and Care Excellence; 2008. p. 36.
- National Institute for Health and Care Excellence. Single technology appraisal: user guide for company evidence submission template - April 2017: National Institute for Health and Care Excellence; 2017 Available from 2018 Sept 21: https://www.nice.org.uk/process/pmg24/chapter/instructions-for-companies
- National Institute for Health and Care Excellence. Single technology appraisal: document B. Company evidence submission 2017 Available from 2018 Sept 21: https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NICE-technology-appraisal-guidance
- World Bank. Japan international cooperation agency. In: The Global Fund; African Development Bank et al. Universal health coverage in Africa: a framework for action. Tokyo: World Health Organization. 2016. 56.
- World Health Organization. HTA agencies and networks by member states. Geneva, Switzerland: World Health Organization; August 2014. Available from 2014 [16 Jun 2018 Jun 16 https://www.who.int/health-technology-assessment/networks/HTAagenciesandnetworksbyMemberStates082014.pdf?ua=1
- World Health Organization. HTA Focal Points - country survey. Geneva, Switzerland: World Health Organization; 2015. https://www.who.int/health-technology-assessment/HTAFocalPoints_CountrySurvey.pdf?ua=1 Available from 2018 Jun 10.
- World Health Organization. Health technology assessment country profile. Geneva, Switzerland: World Health Organization; 2015. http://www.who.int/health-technology-assessment/country-profile/en/ Available from 2018 Jun 10.
- International Network of Agencies for Health Technology Assessment. INAHTA Members List 2018 Available from 2018 Jun 18: http://www.inahta.org/members/
- Health Technology Assessment International. HTAi vortal 2018 Available from 2018 Apr 1: http://vortal.htai.org/?q=africa
- International Society for Pharmacoeconomics and Outcomes Research. The ISPOR global health care systems road map 2018 Available from 2018 Jul 18: https://tools.ispor.org/htaroadmaps/
- International Society for Pharmacoeconomics and Outcomes Research. Pharmacoeconomic guidelines around the world 2018 Available from 2018 Jul 30: https://tools.ispor.org/peguidelines/
- International Society for Pharmacoeconomics and Outcomes Research. ISPOR chapters 2018 Available from 2018 Jul 2: https://www.ispor.org/member-groups/global-groups/regional-chapters
- Pienaar E, Grobler L, Busgeeth K, et al. Developing a geographic search filter to identify randomised controlled trials in Africa: finding the optimal balance between sensitivity and precision. Health Info Libr J. 2011 Sep;28(3):210–215.
- EUnetHTA Joint Action 2 WP. HTA core model(R) version 3 (pdf) 2016 Available from 2018 Mar 18: https://www.eunethta.eu/wp-content/uploads/2018/03/HTACoreModel3.0-1.pdf
- Kristensen FB, Lampe K, Wild C, et al. The HTA core model-10 years of developing an international framework to share multidimensional value assessment. Value Health. 2017 Feb;20(2):244–250.
- Elsisi GH, Kaló Z, Eldessouki R, et al. Recommendations for reporting pharmacoeconomic evaluations in Egypt. Value Health Reg Issues. 2013 Sep - Oct;2(2):319–327.
- Ministry of Health and Population. Guidelines for reporting pharmacoeconomic evaluations (version 1). Available from 2018 Sept 2: http://www.eda.mohp.gov.eg/Files/402_Egyptian_Pharmacoeconomic_guidelines.pdf
- Faria R, Hernandez Alava M, Manca A, et al. NICE DSU technical support unit 17: the use of observational data to inform estimates of treatment effectiveness in technology appraisal: Methods for comparative individual patient data. Sheffield: University of Sheffield; 2015. p. 86.
- Bell H, Wailoo AJ, Hernandez M, et al. The use of real world data for the estimation of treatment effects in NICE decision- making. Sheffield: University of Sheffield; 2016. p. 60.
- National Institute for Health and Care Excellence. NICE highly specialised technologies guidance: National Institute for Health and Care Excellence; 2019 Available from 2019 Jan 21: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-highly-specialised-technologies-guidance
- Pennington B, Ren S, Barton S, et al. Dinutuximab beta for treating neuroblastoma: an evidence review group and decision support unit perspective of a NICE single technology appraisal. Pharmacoeconomics. 2018 Nov;22.
- Devi S. Universal health coverage law approved in Egypt. Lancet. 2018 Jan 20;391(10117):194.
- Babigumira JB, Jenny AM, Bartlein R, et al. Health technology assessment in low‐and middle‐income countries: a landscape assessment. J Pharm Health Serv Res. 2016;7(1):37–42.
- Oyebode O, Garrett Z, George E, et al. Evidence requirements for reimbursement of pharmaceuticals across Europe. Int J Technol Assess Health Care. 2015 Jan;31(1–2):59–67.
- Pasternack I, de Groot I, Kleijnen S, et al. Comparing the HTA core model with a national health technology assessment report. Int J Technol Assess Health Care. 2014 Nov;30(5):530–535.
- Korge K, Berndt N, Hohmann J, et al. Evaluation of the HTA core model for national health technology assessment reports: comparative Study and experiences from European countries. Int J Technol Assess Health Care. 2017 Jan;33(6):644–653.
- Kristensen FB, Husereau D, Huic M, et al. Identifying the need for good practices in health technology assessment: summary of the ISPOR HTA council working group report on good practices in HTA. Value Health. 2019 Jan;22(1):13–20.
- Hofmann B, Cleemput I, Bond K, et al. Revealing and acknowledging value judgments in health technology assessment. Int J Technol Assess Health Care. 2014 Dec;30(6):579–586.
- Whyte P, Hall C WHO/HAI project on medicine prices and availability. Working Paper 6: The Role of Health Technology in Medicine Pricing and Reimbursement. Review Series on Pharmaceutical Pricing Policies and Interventions. Melbourne, Australia: Deakin University; 2013. p. 56.
- Wilkinson M, Wilkinson T, Kredo T, et al. South African clinical practice guidelines: A landscape analysis. S Afr Med J. 2017 Dec 13;108(1):23–27.
- International Society for Pharmacoeconomics and Outcomes Research. Saudi Arabia regional chapter 2019 Available from 2019 Jan 27: https://www.ispor.org/member-groups/global-groups/regional-chapters/saudi-arabia
- Gyldmark M, Lampe K, Ruof J, et al. Is the EUnetHTA HTA Core Model fit for purpose? Evaluation from an industry perspective. Int J Technol Assess Health Care. 2018 January;34(5):458–463.